CYP2C19 Pharmacogenomic Genotyping to Direct Clopidogrel Therapy for Secondary Prevention in Patients with a History of Stroke and/or Transient Ischemic Attack (TIA)

This report evaluates the clinical utility for CYP2C19 pharmacogenomic genotyping to direct clopidogrel therapy for secondary prevention in adult patients who have experienced a stroke or transient ischemic attack (TIA).

If you have a Hayes login, click here to view the full report on the Knowledge Center.